<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="174175">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828451</url>
  </required_header>
  <id_info>
    <org_study_id>08-0105</org_study_id>
    <nct_id>NCT00828451</nct_id>
  </id_info>
  <brief_title>Collaborative Research Group for Necrotizing Enterocolitis</brief_title>
  <official_title>Collaborative Research Group for Necrotizing Enterocolitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal will test the hypothesis that synthesis and catabolism of epidermal growth
      factor, the genotype of the EGF gene, and the microbiome interact to influence EGF
      expression in infants at risk for necrotizing enterocolitis (NEC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Preterm infants will receive a six hour intravenous infusion of [5,5,5-2H3]leucine
           through an existing intravenous line (IV) to measure EGF synthesis rate.

        -  Two blood samples will be obtained, one prior to the start of infusion, and one during
           the infusion. The enrichment of the stable isotope labeled leucine will be measured in
           the plasma from these samples; DNA will be extracted from the residual cell pellets.
           The EGF and EGF receptor genes will be sequenced.

        -  Saliva and urine will be obtained for 5 days following infusion to measure EGF and the
           rate of incorporation of leucine into EGF using LC/MS/MS technology. Saliva will be
           obtained by a Q tip swab and urine and stool obtained from the diaper.

        -  Stool will be obtained every 3 to 7 days through 5 weeks to evaluate inflammatory
           markers and the microbiome.

        -  If breastfeeding, a single sample of mother's milk will be obtained for measurement of
           EGF after adequate volumes for infant feeds are achieved.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rate of EGF synthesis and catabolism</measure>
    <time_frame>1 week of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>EGF genotype</measure>
    <time_frame>1 week of age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>composition of the microbiome</measure>
    <time_frame>weekly from birth to 6 weeks of age</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Prematurity</condition>
  <condition>Necrotizing Enterocolitis</condition>
  <arm_group>
    <arm_group_label>NEC study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Premature infants born at &lt; 32 weeks gestation who are 7 days old or less.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>[5,5,5-2H3]leucine (stable isotope labeled leucine)</intervention_name>
    <description>intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total</description>
    <arm_group_label>NEC study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gestation 32 weeks or less

          -  1 week of age or less

          -  intravenous line in place for clinical purposes

        Exclusion Criteria:

          -  imminent death

          -  active infection

          -  pre-existing diagnosis of NEC

          -  fluid or electrolyte imbalance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Hamvas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nair RR, Warner BB, Warner BW. Role of epidermal growth factor and other growth factors in the prevention of necrotizing enterocolitis. Semin Perinatol. 2008 Apr;32(2):107-13. doi: 10.1053/j.semperi.2008.01.007. Review.</citation>
    <PMID>18346534</PMID>
  </reference>
  <reference>
    <citation>Warner BB, Ryan AL, Seeger K, Leonard AC, Erwin CR, Warner BW. Ontogeny of salivary epidermal growth factor and necrotizing enterocolitis. J Pediatr. 2007 Apr;150(4):358-63.</citation>
    <PMID>17382110</PMID>
  </reference>
  <reference>
    <citation>Spence KL, Zozobrado JC, Patterson BW, Hamvas A. Substrate utilization and kinetics of surfactant metabolism in evolving bronchopulmonary dysplasia. J Pediatr. 2005 Oct;147(4):480-5.</citation>
    <PMID>16227034</PMID>
  </reference>
  <reference>
    <citation>Bohlin K, Patterson BW, Spence KL, Merchak A, Zozobrado JC, Zimmermann LJ, Carnielli VP, Hamvas A. Metabolic kinetics of pulmonary surfactant in newborn infants using endogenous stable isotope techniques. J Lipid Res. 2005 Jun;46(6):1257-65. Epub 2005 Mar 16.</citation>
    <PMID>15772427</PMID>
  </reference>
  <verification_date>December 2009</verification_date>
  <lastchanged_date>December 17, 2009</lastchanged_date>
  <firstreceived_date>January 22, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Aaron Hamvas, MD</name_title>
    <organization>Washington University School of Medicine</organization>
  </responsible_party>
  <keyword>newborn</keyword>
  <keyword>necrotizing enterocolitis</keyword>
  <keyword>genetics</keyword>
  <keyword>growth factors</keyword>
  <keyword>metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
    <mesh_term>Enterocolitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
